P53 mutations in stromal fibroblasts sensitize tumors against chemotherapy.
Int J Cancer
; 123(4): 967-71, 2008 Aug 15.
Article
em En
| MEDLINE
| ID: mdl-18512237
ABSTRACT
The efficacy of chemotherapy is usually viewed as the outcome of cancer-cell-autonomous processes while the contribution of stroma is being overseen. Here we show that p53 mutations in stromal fibroblasts, a genetic lesion that is detectable in primary breast, prostate and probably other cancers, while they accelerate tumorigenesis they also sensitize tumours against conventional chemotherapy by doxorubicin and cis-platinum. The mechanism by which p53 of stromal fibroblasts affects the response of a tumour against chemotherapy is likely to involve the induction of senescence in the fibroblasts which in turns results in the production of growth factors acting onto the cancer cells by paracrine mechanisms. Our findings identify stromal fibroblasts as important modulators of the efficacy of anticancer therapy.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Próstata
/
Neoplasias da Mama
/
Adenocarcinoma
/
Proteína Supressora de Tumor p53
Tipo de estudo:
Prognostic_studies
Limite:
Animals
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Int J Cancer
Ano de publicação:
2008
Tipo de documento:
Article
País de afiliação:
Grécia